Founded in May 1991, Myriad Genetics'''' strategy is to understand the role of genes in human disease and then use that information to develop and commercialize products that assess a person''''s risk of developing disease later in life and guide treatment decisions based on an individual''''s genetic makeup and specific cause of disease. The company soon emerged as a world leader in the new field of molecular diagnostics. Going forward, Myriad is uniquely positioned to develop and commercialize new molecular diagnostics that prevent or mitigate the toll of mankind''''s deadliest diseases, such as cancer.